In the last trading session, 1.04 million shares of the Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) were traded, and its beta was 0.25. Most recently the company’s share price was $1.08, and it changed around $0.0 or 0.00% from the last close, which brings the market valuation of the company to $8.57M. BCLI currently trades at a discount to its 52-week high of $8.91, offering almost -725.0% off that amount. The share price’s 52-week low was $0.72, which indicates that the current value has risen by an impressive 33.33% since then. We note from Brainstorm Cell Therapeutics, Inc’s average daily trading volume that its 10-day average is 6.47 million shares, with the 3-month average coming to 1.16 million.
Brainstorm Cell Therapeutics, Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended BCLI as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight.
Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) trade information
The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.3400 on recent trading dayincreased the stock’s daily price by 19.4%. The company’s shares are currently down -52.42% year-to-date, but still down -20.59% over the last five days. On the other hand, Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) is 10.77% up in the 30-day period. We can see from the shorts that 0.29 million shares have been sold at a short interest cover period of 0.76 day(s).
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 32.00%. Brainstorm Cell Therapeutics, Inc earnings are expected to increase by 30.74% in 2025, but the outlook is positive 29.48% per year for the next five years.
BCLI Dividends
Brainstorm Cell Therapeutics, Inc’s next quarterly earnings report is expected to be released on 2025-May-14.
Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 15.98% of Brainstorm Cell Therapeutics, Inc shares, and 12.89% of them are in the hands of institutional investors. The stock currently has a share float of 15.34%. Brainstorm Cell Therapeutics, Inc stock is held by 34.0 institutions, with ARMISTICE CAPITAL, LLC being the largest institutional investor. By 2024-06-30, it held 11.1179% of the shares, which is about 7.92 million shares worth $2.68 million.
VANGUARD GROUP INC, with 2.1212% or 1.51 million shares worth $0.51 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund were the top two Mutual Funds as of Dec 31, 2024 . The former held 50.72 shares worth $54774.0, making up 0.64% of all outstanding shares. On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund held roughly 31.71 shares worth around $34251.0, which represents about 0.40% of the total shares outstanding.
